Beat AML is a groundbreaking collaboration between Blood Cancer United, academic institutions, and pharma/biotech collaborators to advance novel therapies and transform standard of care for patients with AML.
Collaborate with Beat AML
Beat AML offers a collaborative, streamlined trial model that helps pharma and biotech partners evaluate new treatments for newly diagnosed or relapsed AML and Myelodysplastic (MDS) patients.
The Beat AML Master Clinical Trial continues to grow by:
- Testing novel therapeutics or combination therapies
- Enrolling relapsed/refractory patients in addition to newly diagnosed patients
- Exploring ways to reduce side effects and improve patients’ quality of life
- Making clinical trials more patient friendly by using new technology to monitor vital signs, symptoms, and side effects of treatment with fewer trips to the doctor
How Beat AML works with
pharma/biotech collaborators.
Beat AML welcomes additional sites to
the expanding Beat AML site network.
Beat AML Master Clinical Trial Design
The Beat AML Master Clinical Trial uses advanced technology to examine the genetic make-up of each patient’s cancer and then matches patients to the most promising targeted treatment.
Over 20,000 Americans are diagnosed each year with acute myeloid leukemia (AML) , making it one of the most common types of leukemia. And one of the most aggressive.
In 2016, Blood Cancer United launched the Beat AML Master Clinical Trial, to move people away from one-size-fits-all chemotherapy. Beat AML established a cost-efficient, unified infrastructure to expedite the clinical development of novel therapies for AML patients.
And your organization may be able to participate by joining the expanding Beat AML site network.
Patient story
Beat AML® news and highlights
News July 30, 2026
Beat AML® Study Provides New Data on 14-Day vs. 28-Day Venetoclax-Azacitidine Treatment in AML
Clinicians often reduce the duration of venetoclax because of side effects, but study finds 14-day schedule fell short in older patients with newly di…
News May 28, 2026
Blood Cancer United-funded researchers will present findings spanning novel treatment approaches and optimization strategies, real-world access and co…
News May 5, 2026
Grant will scale AI‑driven automation for regulatory documentation to help accelerate clinical research.
News January 14, 2026
Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment
In collaboration with AVEO Oncology, an LG Chem company, (“AVEO”) the new Beat AML sub-study is evaluating ficlatuzumab, a monoclonal antibody targeti…
News December 5, 2025
FDA Expands Drug’s Approval To Include More People With AML
Blood Cancer United funding supported discovery and development of breakthrough menin inhibitors.
Current active sub-studies of Beat AML Master Trial (NCT03013998)
The following sub-studies are currently open:
BAML-16-001-S17
Phase 1b dose escalation/expansion
Revumenib + Azacitidine + Venetoclax
Newly Diagnosed unfit AML, NPM1m. KMT2Ar.
Active, enrollment completed
BAML-16-001-S24
Phase 1b safety run in/Phase 2
FiclatuZumab + Azacitidine + Venetoclax
Newly Diagnosed AML, all types
Actively recruiting
BAML-16-001-S25/HO181
Phase 3
Bleximenib + Induction/Consolidation
Newly Diagnosed fit AML, NPM1m. KMT2Ar.
Actively recruiting
BAML-16-001-S26/HO177
Phase 3
Revumenib + Azacitidine + Venetoclax
Newly Diagnosed unfit AML, NPM1m. KMT2Ar.
Actively recruiting
Screened >1900 patients on the Master Clinical Trial protocol and enrolled >700 patients onto sub-protocols
17 sub-protocols to date with 4 currently active
Multiple high impact publications with practice changing insights: 21 Journal articles (Nature Med., Blood Advances, Cancer) 36 Abstracts (ASH, EHA, ASCO, SOHO)
Meet the Beat AML steering committee
Brian Druker, MD
Chief Executive Officer
Knight Cancer Institute
Oregon Health & Science University
Ross L. Levine, MD
Chief Executive Officer
Memorial Sloan Kettering Cancer Center
Ashley Yocum, PhD
VP Clinical Research Beat AML
Blood Cancer United
Alice Mims, MD, MSCR
Beat AML Chief Medical Officer
Professor, The Ohio State University
Uma Borate, MBBS, MS
Beat AML Chief Strategic Officer
Clinical Professor, The Ohio State University
Lore Gruenbaum, PhD
SVP, Chief Scientific Officer
Blood Cancer United
Join an AML clinical trial as a patient
If you or someone you love has AML, our team can help you understand available trial options and whether you may qualify.
Current Beat AML core sites
The Ohio State University
Oregon & Health Science University
Memorial Sloan Kettering Cancer Center
University of Maryland, Baltimore
University of Chicago
University of Texas Southwestern
University of California, San Francisco
Emory University
University of California, Los Angeles
University of Kansas Medical Center
University of North Carolina, Chapel Hill
University of Cincinnati
University of Pittsburgh Medical Center
Resources
Discover resources especially developed for people with AML, including booklets and fact sheets, podcasts, webcasts, videos, interactive 3D models, support services, and more.
Or find blood cancer resources for caregivers and healthcare professionals.
Donate
Help expand the impact of Beat AML for patients and families by making a gift to Blood Cancer United.
